Roche announces final results of tender offer for Foundation Medicine, Inc.
The shares purchased by Roche in the tender offer total approximately 21,019,111 shares.
PRESS RELEASE
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the final results of the tender offer by Roche Holdings, Inc., its wholly owned subsidiary, to purchase up to 15,604,288 shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at USD 50.00 per share in cash, which expired at 12:00 midnight, New York City time, at the end of the day on 6 April 2015. The shares purchased by Roche in the tender offer, when added to the shares already owned by Roche and its affiliates (including 5,000,000 shares issued by FMI to Roche on 7 April 2015), total approximately 21,019,111 shares, representing approximately 57% of the outstanding shares of FMI’s common stock on a fully diluted basis as of 7 April 2015.
Based on the final tabulation by Citibank, N.A., the depositary for the tender offer, a total of 18,758,256 shares of FMI’s common stock were validly tendered and not validly withdrawn in the tender offer. Because the tender offer was oversubscribed, the number of shares accepted for purchase by Roche from each of the tendering stockholders has been prorated. The final proration factor is 83.186197%.
